Medtronic began by repairing hospital electronics in a Minneapolis garage. Seventy-seven years later, its devices sit inside bodies, beside beds, and at the center of a high-stakes contest to make medicine less invasive, more measurable, and easier to scale.
Procyrion, Inc. is a Houston-based medical device company developing Aortix, a catheter-delivered percutaneous mechanical circulatory support (pMCS) pump. About the width of a pencil, Aortix is anchored in the descending aorta where it unloads the failing heart while boosting blood flow to the kidneys, targeting acute decompensated heart failure and cardiorenal syndrome. The device holds FDA Breakthrough Device Designation and is in the DRAIN-HF pivotal IDE trial after closing a $57.7M Series E in February 2024.